Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
Abbott’s global CGM correction intensifies regulatory scrutiny while Novartis extends Itvisma to older SMA patients and CytomX signals renewed ADC momentum November 25, 2025 encapsulated
Novartis extends SMA gene therapy beyond infancy while Abbott’s 3-million-unit sensor correction triggers industry-wide accuracy scrutiny Today marked a pivotal intersection of breakthrough and caution
Abbott acquires Exact Sciences for ~$21B equity, $23B enterprise value in landmark diagnostics deal; Cologuard and Oncotype DX franchises reshape Abbott’s cancer screening footprint; diagnostics-AI
FDA Approvals in HER2-Mutated Lung Cancer and Rare Disease Expand Treatment Arsenal While AI Investment Surges and Medtech Innovation Accelerates An exhaustive examination of regulatory
FDA approves Arrowhead’s plozasiran for ultra-rare FCS; expands epcoritamab in follicular lymphoma; Medtronic raises guidance on >300% PFA growth breaking $100 share price; GLP-1 pricing
Johnson & Johnson’s $3.05B Halda acquisition secures RiPTAC platform; FDA approves first interchangeable Perjeta biosimilar; Nuvalent’s ALK inhibitor delivers pivotal durability; NIH grant terminations disrupt
FDA’s “plausible mechanism” pathway transforms ultra-rare therapeutics; Siemens dramatically reduces Healthineers stake in €33.5B restructuring; gene editing platforms consolidate as capital rotates toward tools and
FDA unveils “plausible mechanism” approval route for ultra-rare therapies; gene editing biotechs restructure amid capital constraints; medtech delivers strong quarters; EU AI regulations tighten device
Richard Pazdur’s CDER appointment signals regulatory evolution; China’s biotech resurgence opens cross-border opportunities; medtech financing hits $26.6B as capital markets normalize The life sciences sector
Trump administration reprices obesity drugs at 75% discount; FDA reverses two decades of HRT warnings; Intellia patient death triggers Cas9 safety debate; and Trodelvy stumbles
